Veru Inc is a late clinical-stage biopharmaceutical focused on developing medicines for the treatment of cardiometabolic and inflammatory diseases... Show more
a manufacturer of female condoms
Industry Biotechnology
| 1 Day | |||
|---|---|---|---|
| ETFs / NAME | Price $ | Chg $ | Chg % |
| PBJ | 44.96 | 0.18 | +0.40% |
| Invesco Food & Beverage ETF (PBJ) | |||
| ICRC | 17.42 | N/A | N/A |
| Bitwise Crcl Option Income Strategy ETF | |||
| FTMA | 8.52 | N/A | N/A |
| Franklin Massachusetts Municipal Income ETF (FTMA) | |||
| DFII | 14.25 | -0.05 | -0.37% |
| Ft Vest Bitcoin Strategy & Target Income ETF | |||
| ISPY | 47.62 | -0.18 | -0.38% |
| ProShares S&P 500 High Income ETF (ISPY) | |||
A.I.dvisor indicates that over the last year, VERU has been loosely correlated with INDP. These tickers have moved in lockstep 48% of the time. This A.I.-generated data suggests there is some statistical probability that if VERU jumps, then INDP could also see price increases.
| Ticker / NAME | Correlation To VERU | 1D Price Change % | ||
|---|---|---|---|---|
| VERU | 100% | -4.51% | ||
| INDP - VERU | 48% Loosely correlated | -7.83% | ||
| ABCL - VERU | 40% Loosely correlated | -4.66% | ||
| RXRX - VERU | 37% Loosely correlated | -1.45% | ||
| ABSI - VERU | 36% Loosely correlated | -0.19% | ||
| PRAX - VERU | 35% Loosely correlated | -1.48% | ||
More | ||||
VERU saw its Momentum Indicator move above the 0 level on September 24, 2026. This is an indication that the stock could be shifting in to a new upward move. Traders may want to consider buying the stock or buying call options. Tickeron's A.I.dvisor looked at 94 similar instances where the indicator turned positive. In 80 of the 94 cases, the stock moved higher in the following days. The odds of a move higher are at 85%.
The Moving Average Convergence Divergence (MACD) for VERU just turned positive on September 25, 2026. Looking at past instances where VERU's MACD turned positive, the stock continued to rise in 33 of 40 cases over the following month. The odds of a continued upward trend are 82%.
VERU moved above its 50-day moving average on September 24, 2026 date and that indicates a change from a downward trend to an upward trend.
The 10-day moving average for VERU crossed bullishly above the 50-day moving average on October 01, 2026. This indicates that the trend has shifted higher and could be considered a buy signal. In 15 of 21 past instances when the 10-day crossed above the 50-day, the stock continued to move higher over the following month. The odds of a continued upward trend are 71%.
The 50-day moving average for VERU moved above the 200-day moving average on September 25, 2026. This could be a long-term bullish signal for the stock as the stock shifts to an upward trend.
Following a +5.35% 3-day Advance, the price is estimated to grow further. Considering data from situations where VERU advanced for three days, in 202 of 244 cases, the price rose further within the following month. The odds of a continued upward trend are 83%.
The Stochastic Oscillator demonstrated that the ticker has stayed in the overbought zone for 5 days. The longer the ticker stays in the overbought zone, the sooner a price pull-back is expected.
Following a 3-day decline, the stock is projected to fall further. Considering past instances where VERU declined for three days, the price rose further in 50 of 62 cases within the following month. The odds of a continued downward trend are 89%.
VERU broke above its upper Bollinger Band on September 30, 2026. This could be a sign that the stock is set to drop as the stock moves back below the upper band and toward the middle band. You may want to consider selling the stock or exploring put options.
The Tickeron Price Growth Rating for this company is 59 (best 1 - 100 worst), indicating steady price growth. VERU’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.
The Tickeron PE Growth Rating for this company is 74 (best 1 - 100 worst), pointing to slightly better than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.
The Tickeron Valuation Rating of 97 (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (1.517) is normal, around the industry mean (26.780). P/E Ratio (0.407) is within average values for comparable stocks, (43.395). VERU's Projected Growth (PEG Ratio) (421.660) is very high in comparison to the industry average of (9.059). Dividend Yield (0.000) settles around the average of (0.000) among similar stocks. P/S Ratio (1.966) is also within normal values, averaging (438.009).
The Tickeron SMR rating for this company is 98 (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.
The Tickeron Profit vs. Risk Rating rating for this company is 100 (best 1 - 100 worst), indicating that the returns do not compensate for the risks. VERU’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock worse than average.